Breaking Finance News

Tiziana Life Sciences Plc (LON:TILS) has been retained to Speculative Buy in a report by Beaufort Securities today.

Beaufort Securities has retained Tiziana Life Sciences Plc (LON:TILS) to Speculative Buy in a statement released on 09/30/2016.

Boasting a price of 192.63GBX, Tiziana Life Sciences Plc (LON:TILS) traded 1.33% higher on the day. The last stock close price is up 19.86% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Tiziana Life Sciences Plc has recorded a 50-day average of 190.67GBX and a two hundred day average of 158.52GBX. Volume of trade was down over the average, with 3,318 shares of TILS changing hands under the typical 4,441

Recent Performance Chart

Tiziana Life Sciences Plc (LON:TILS)

Tiziana Life Sciences Plc has with a one year low of 91.35GBX and a one year high of 232.95GBX and has a market capitalization of 0 GBX.

A total of 1 brokerage has released a report on the stock. 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of 45.00GBX.

Brief Synopsis On Tiziana Life Sciences Plc (LON:TILS)

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its products in clinical stage include Milciclib and Foralumab. Its products in pre-clinical stage include TZLS-101 and TZLS-214. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib is in Phase II clinical trials for thymic carcinoma. The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. The Company is involved in the development of Bcl-3 inhibitors. The Company's lead clinical candidate, CB1, is a Bcl-3 inhibitor with potent anti-metastatic activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.